The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS
Scatchard, G. (1949) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1949.tb27297.x · Cited by 19,778
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Pharmacologic Analysis of Drug Receptor Interaction
Kenakin, K. T. (1988) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198803000-00029 · Cited by 927
Distinct functions of the two isoforms of dopamine D2 receptors
Usiello, A., Baik, J.-H., Rougé-Pont, F., Picetti, R., Dierich, A., LeMeur, M., Piazza, P. V., & Borrelli, E. (2000) · Nature · doi:10.1038/35041572 · Cited by 717
Furchgott, R. F., & Bursztyn, P. (1967) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1967.tb53817.x · Cited by 522
Berg, K. A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P., & Clarke, W. P. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.94 · Cited by 510
Lawler, C. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00099-2 · Cited by 408
Kikuchi, T., Tottori, K., Uwahodo, Y., Hirose, T., Miwa, T., Oshiro, Y., & Morita, S. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10600-9 · Cited by 276
Self-citationReceptor Occupancy and Tissue Response
NICKERSON, M. (1956) · Nature · doi:10.1038/178697b0 · Cited by 242
Cited by
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,116
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Half a century of antipsychotics and still a central role for dopamine D2 receptors
Kapur, S., & Mamo, D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.004 · Cited by 638
The neurobiology of psychopathic traits in youths
Blair, R. J. R. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3577 · Cited by 614
Potkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M., Stock, E., Stringfellow, J., Ingenito, G., & Marder, S. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.681 · Cited by 591
Current Concepts and Treatments of Schizophrenia
Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018) · Molecules · doi:10.3390/molecules23082087 · Cited by 556
Krystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530
Marcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518
Dopamine: 50 years in perspective
Iversen, S. D., & Iversen, L. L. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.002 · Cited by 518
Keck, P. E., Marcus, R., Tourkodimitris, S., Ali, M., Liebeskind, A., Saha, A., Ingenito, G., & Aripiprazole Study Group (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1651 · Cited by 501
Marder, S. R., McQuade, R. D., Stock, E., Kaplita, S., Marcus, R., Safferman, A. Z., Saha, A., Ali, M., & Iwamoto, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00050-1 · Cited by 467
the ESSTS Guidelines Group, Roessner, V., Plessen, K. J., Rothenberger, A., Ludolph, A. G., Rizzo, R., Skov, L., Strand, G., Stern, J. S., Termine, C., et al. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-011-0163-7 · Cited by 461
Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia
Horacek, J., Bubenikova-Valesova, V., Kopecek, M., Palenicek, T., Dockery, C., Mohr, P., & H??schl, C. (2006) · CNS Drugs · doi:10.2165/00023210-200620050-00004 · Cited by 461
Update on Typical and Atypical Antipsychotic Drugs
Meltzer, H. Y. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050911-161504 · Cited by 433
Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns?
Pacher, P., & Kecskemeti, V. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383872 · Cited by 390
Kaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Maeda, K., Sugino, H., Akazawa, H., Amada, N., Shimada, J., Futamura, T., Yamashita, H., Ito, N., McQuade, R. D., Mørk, A., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213793 · Cited by 372
Self-citationConduct disorder and callous-unemotional traits in youth
Blair, R. J. R., Leibenluft, E., & Pine, D. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1315612 · Cited by 371
Kiss, B., Horváth, A., Némethy, Z., Schmidt, É., Laszlovszky, I., Bugovics, G., Fazekas, K., Hornok, K., Orosz, S., Gyertyán, I., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160432 · Cited by 367
Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability
DeLeon, A., Patel, N. C., & Lynn Crismon, M. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90066-5 · Cited by 363
Mareev, V. Y., Medical Scientific and Educational Centre of Moscow State University, Fomin, I. V., Federal State Budgetary Educational Institution of Higher Education, ". N. S. M. A. O. T. M. O. H. O. T. R. F., Ageev, F. T., Federal State Budgetary Institution, ". C. S. A. P. C. O. T. M. O. H. O. T. R. F., Begrambekova, Y. L., Federal State Budgetary Educational Institution of Higher Education, ". V. L. M. S. U., Vasyuk, Y. A., Federal State Budgetary Educational Institution of Higher Education, ". I. E. M. S. U. F. M. A. D. O. T. M. O. H. O. T. R. F., et al. (2018) · Kardiologiia · doi:10.18087/cardio.2475 · Cited by 361
Kane, J. M., Sanchez, R., Perry, P. P., Jin, N., Johnson, B. R., Forbes, R. A., McQuade, R. D., Carson, W. H., & Fleischhacker, W. W. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07530 · Cited by 361
Dopamine Partial Agonists: A New Class of Antipsychotic
Lieberman, J. A. (2004) · CNS Drugs · doi:10.2165/00023210-200418040-00005 · Cited by 340
Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Mailman, R., & Murthy, V. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361461 · Cited by 311
Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
Snyder, G. L., Vanover, K. E., Zhu, H., Miller, D. B., O’Callaghan, J. P., Tomesch, J., Li, P., Zhang, Q., Krishnan, V., Hendrick, J. P., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3704-1 · Cited by 289
Aripiprazole: A Review of its Use in Schizophrenia and Schizoaffective Disorder
Swainston Harrison, T., & Perry, C. M. (2004) · Drugs · doi:10.2165/00003495-200464150-00010 · Cited by 276
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Correll, C. U. (2010) · European Psychiatry · doi:10.1016/s0924-9338(10)71701-6 · Cited by 273
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Li, P., L. Snyder, G., & E. Vanover, K. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160608084834 · Cited by 266
The dopamine hypothesis of drug addiction and its potential therapeutic value
Diana, M. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00064 · Cited by 251
Thase, M. E., Jonas, A., Khan, A., Bowden, C. L., Wu, X., McQuade, R. D., Carson, W. H., Marcus, R. N., & Owen, R. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181618eb4 · Cited by 251
Clinical pharmacology of atypical antipsychotics: an update
Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., & Altamura, A. C. (2014) · Technische Universität Dortmund · doi:10.17877/de290r-7037 · Cited by 250
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
Sayyah, M., Sayyah, M., Boostani, H., Ghaffari, S. M., & Hoseini, A. (2012) · Depression and Anxiety · doi:10.1002/da.21996 · Cited by 105
Tadokoro, S., Okamura, N., Sekine, Y., Kanahara, N., Hashimoto, K., & Iyo, M. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr006 · Cited by 92
Tadori, Y., Kitagawa, H., Forbes, R. A., McQuade, R. D., Stark, A., & Kikuchi, T. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.07.031 · Cited by 69
Self-citationA prospective open-label study of aripiprazole in fragile X syndrome
Erickson, C. A., Stigler, K. A., Wink, L. K., Mullett, J. E., Kohn, A., Posey, D. J., & McDougle, C. J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2194-7 · Cited by 69
Aripiprazole in Autism Spectrum Disorders and Fragile X Syndrome
Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.04.001 · Cited by 65
Carlson, B. X., Ketter, T. A., Sun, W., Timko, K., McQuade, R. D., Sanchez, R., Vester‐Blokland, E., & Marcus, R. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00974.x · Cited by 63
A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine
Stoops, W. W., Lile, J. A., Glaser, P. E. A., & Rush, C. R. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.02.004 · Cited by 57
Aboraya, A., & Nasrallah, H. A. (2016) · Annals of Clinical Psychiatry · doi:10.1177/104012371602800206 · Cited by 46
Raoufinia, A., Peters-Strickland, T., Nylander, A.-G., Baker, R. A., Eramo, A., Jin, N., Bricmont, P., Repella, J., McQuade, R. D., Hertel, P., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw116 · Cited by 39
Choi, H., Kim, J. H., Yang, H. S., Kim, J. Y., Cortese, S., Smith, L., Koyanagi, A., Dragioti, E., Radua, J., Fusar-Poli, P., et al. (2024) · Molecular Autism · doi:10.1186/s13229-024-00585-6 · Cited by 37
“It has not only a 5HT 2A receptor antagonistic effect but also partial agonistic effects on the D2 dopamine receptor and 5HT 1A serotonin receptor [27].”
BackgroundSugawara Kikuchi, Y., & Shimizu, T. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s189050 · Cited by 14
Metadata
- Authors
- Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2002-07
- Volume
- 302
- Issue
- 1
- Pages
- 381-389
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W1971179661
- Cited by
- 922
- References
- 35
- FWCI
- 12.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.